Subcutaneous Tislelizumab
BGB-A317-316
Phase 3 small_molecule active
Quick answer
Subcutaneous Tislelizumab for Metastatic Gastric Adenocarcinoma is a Phase 3 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Metastatic Gastric Adenocarcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active